Wisp’s menopause pages bring together consultations, prescription products and other support items. Among them is a named nonhormonal vaginal moisturizer. That makes the service relevant to a discussion of hormone-free care, but it does not establish a particular nonhormonal prescription for hot flashes.
Reviewed September 29, 2026, this assessment follows the difference between those two treatment goals. It considers the moisturizer listing, the separate menopause consultation and published purchase terms. We have not tested the product, received a prescription or verified an individual’s eligibility. The listing’s specific cautions and unresolved formulation details remain more useful than treating all nonhormonal offerings as one category.
Begin with local discomfort rather than a general menopause promise
The moisturizer page identifies vaginal dryness as its concern. That local purpose should stay separate from reducing hot flashes or night sweats. Wisp’s page does not provide evidence that this product treats vasomotor symptoms, and this review makes no such inference. The medicine-family guide concerns another set of treatment questions. A reader comparing services should first establish whether the problem being discussed is the same. Otherwise, a hormone-free local product and an oral hot-flash medicine can appear to be competing answers when the public records describe different purposes and different clinical considerations.
A prescription badge does not provide the entire product record
Wisp labels its Non-Hormonal Vaginal Moisturizer as a prescription offering. The reviewed description does not supply a complete ingredient statement or a product-specific approval record. We therefore do not infer either from the badge or from the phrase hormone-free. The page makes broad suitability and effectiveness claims; those are the seller’s statements, not findings from independent product testing here. An ingredient concern requires the formulation actually proposed. The service should explain what the product contains and provide the relevant patient information before marketing language is treated as a complete basis for a personal decision. The product’s broad references to postpartum, breastfeeding and menopause also do not answer an individual suitability question. Those life-stage categories can encompass different concerns and medical circumstances. A specific question about the proposed product belongs with the treating professional; the website description cannot establish that a reader’s symptoms have been evaluated or that its formulation is appropriate.
The latex-condom caution belongs beside the reassuring description
The product page specifically warns against use with latex condoms because its oil base may affect condom efficacy. That caution should not disappear behind language suggesting broad suitability across life stages. It is a source-attributed product limitation, not a compatibility assessment this review has performed for any individual. Ask the responsible professional to explain the actual formulation and relevant precautions. Our Stella review examines a more general nonhormonal clinical menu. Wisp’s more specific local product allows this particular caution to be identified, without establishing that its offer is clinically preferable or appropriate for every person with dryness.
The menopause consultation has a different price and scope
Wisp’s separate consultation page starts at $33 per month and includes the consultation, follow-ups and care-team access. It names hormonal treatment options and directs visitors to broader hormonal and nonhormonal support. That wording does not confirm a particular systemic nonhormonal hot-flash medicine available through the consult. Medicines prescribed for local-pharmacy collection are charged separately. The visit-goals guide helps distinguish the question a visitor wants assessed from a product they have already seen. No prescription is guaranteed, and a same-day transmission statement is not proof that a pharmacy will have the item ready or that its price is covered.
The moisturizer price also leaves a selected purchase unresolved
The specific moisturizer listing begins at $60 and offers a one-time purchase or subscription, with free delivery advertised. The reviewed text does not settle the quantity, renewal period and full selected charge together. We have not chosen an option in checkout. The monthly consultation and the moisturizer listing therefore should not be added into an invented all-inclusive plan. Our Joi assessment considers another broad clinical offer where a relevant service does not establish a specific nonhormonal medicine. In both cases, the unresolved purchase should remain unresolved until the selected terms identify what is actually being bought.
Read recurring-payment and prescription-renewal rules separately
The Wisp terms describe automatically recurring subscriptions, with cancellation required at least forty-eight hours before the next refill or renewal period to avoid its charge. Prescription renewal also requires the relevant intake review and a valid prescription; payment alone does not renew clinical authorization. Product sales are generally final, with discretionary refund or replacement provisions for specified problems such as unavailable, damaged or missing items. Physical returns are not accepted. These are published terms, not a promise that a particular complaint will receive a refund. The selected product and subscription agreement still need to be identified before the general rules can describe a complete financial commitment.
Keep the unverified hot-flash offer out of the conclusion
Wisp’s consultation is a genuine menopause-care service, and the moisturizer is a documented hormone-free local-dryness offer. Those findings do not establish that Wisp supplies a particular systemic nonhormonal medicine for vasomotor symptoms. A prospective patient can ask about that directly, with the intended symptom and relevant history made clear. This review provides no application instructions, ingredient clearance or personal combination advice. Its conclusion is deliberately tied to the two public records: clinical access and a specific local product, with important boundaries around formulation, efficacy, compatibility and selected purchase terms. For a broader prescribing category without a selected product, compare the Gennev assessment; that is a different level of offer specificity.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Wisp: Non-Hormonal Vaginal MoisturizerOfficial specific local-dryness offer and latex-condom caution; marketing does not establish vasomotor efficacy or a complete formulation · Checked 2026-09-29
- Wisp: Menopause Consult OnlineOfficial clinical offer and separately billed local-pharmacy medicines; exact systemic nonhormonal medicine offer unconfirmed · Checked 2026-09-29
- Wisp: terms of useDated platform transaction terms; prescription renewal review, 48-hour cancellation and discretionary product remedies; not individual legal advice · Checked 2026-09-28